Supplemental Evidence and Data Request on Evaluation of Dietary Protein Intake Requirements, 38864-38866 [2023-12677]
Download as PDF
<![CDATA[
38864
Federal Register / Vol. 88, No. 114 / Wednesday, June 14, 2023 / Notices
Æ Should EPA expand the scope of
the strategy to include sea-based
sources?
Æ Should specific types of plastic
products be targeted for reduction or
reuse in this strategy?
• Do you have any additional
information or recommendations for
EPA regarding these or other proposed
actions in this draft strategy?
IV. Disclaimer and Important Note
This request for public comment is
issued solely for information, research
and planning purposes and does not
constitute a Request for Proposals (RFP)
or a Request for Applications (RFA).
Responding to this notice will not give
any advantage to or preclude any
organization or individual in any
subsequently issued solicitation, RFP, or
RFA. Any future development activities
related to this activity will be
announced separately. This notice does
not represent any award commitment on
the part of the U.S. Government, nor
does it obligate the Government to pay
for costs incurred in the preparation and
submission of any responses.
Dated: June 8, 2023.
Carolyn Hoskinson,
Director, Office of Resource Conservation and
Recovery.
[FR Doc. 2023–12684 Filed 6–13–23; 8:45 am]
BILLING CODE 6560–50–P
FEDERAL RESERVE SYSTEM
ddrumheller on DSK120RN23PROD with NOTICES1
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
The notificants listed below have
applied under the Change in Bank
Control Act (Act) (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
applications are set forth in paragraph 7
of the Act (12 U.S.C. 1817(j)(7)).
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in paragraph 7 of
the Act.
VerDate Sep<11>2014
19:24 Jun 13, 2023
Jkt 259001
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than June 29, 2023.
A. Federal Reserve Bank of Kansas
City (Jeffrey Imgarten, Assistant Vice
President) One Memorial Drive, Kansas
City, Missouri. Comments can also be
sent electronically to
KCApplicationComments@kc.frb.org.
1. Michael Taylor, Sundance,
Wyoming; to join the Richard Durfee
Family Control Group, a group acting in
concert, to retain voting shares of
Sundance Bankshares, Inc., and thereby
indirectly retain voting shares of
Sundance State Bank, both of Sundance,
Wyoming.
2. Charles and Loretta Durfee
Revocable Trust, Loretta Durfee and
Charles Durfee, as co-trustees, all of
Sundance, Wyoming; Gerald and Peggy
Hyatt Living Trust, Gerald Hyatt and
Peggy Hyatt, as co-trustees, all of Bar
Nunn, Wyoming; Moline Revocable
Trust, Brett R. Moline and Judy Moline,
as co-trustees, all of Laramie, Wyoming;
and Tranas Family Revocable Trust,
Donald Tranas and Shirley Tranas, as
co-trustees, all of Greybull, Wyoming; to
join the James R. Durfee Family Control
Group, a group acting in concert, to
retain voting shares of Sundance
Bankshares, Inc., and thereby indirectly
retain voting shares of Sundance State
Bank, both of Sundance, Wyoming.
B. Federal Reserve Bank of St. Louis
(Holly A. Rieser, Senior Manager) P.O.
Box 442, St. Louis, Missouri 63166–
2034. Comments can also be sent
electronically to
Comments.applications@stls.frb.org.
1. Lambert Lynn Marshall, Little Rock,
Arkansas; to retain voting shares of
MNB Bancshares, Inc., and thereby
indirectly retain voting shares of The
Malvern National Bank, both of
Malvern, Arkansas.
C. Federal Reserve Bank of Chicago
(Colette A. Fried, Assistant Vice
President) 230 South LaSalle Street,
Chicago, IL 60604. Comments can also
be sent electronically to
Comments.applications@chi.frb.org.
1. Dairyland Bank Holding
Corporation, and William Bosshard,
Andrew Bosshard, Joseph Bosshard,
Makenzie Bosshard, Carlista Bosshard,
and John Bosshard as Tenants in
Common, all of La Crosse, Wisconsin; to
join the Bosshard Family Control Group,
a group acting in concert, to acquire
voting shares of Bosshard Financial
Group, Inc., La Crosse, Wisconsin, and
thereby indirectly acquire voting shares
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
of One Community Bank, Oregon,
Wisconsin, and Farmers State BankHillsboro, Hillsboro, Wisconsin.
D. Federal Reserve Bank of San
Francisco (Joseph Cuenco, Assistant
Vice President) 101 Market Street, San
Francisco, California. 94105–1579.
Comments can also be sent
electronically to:
sf.fisc.comments.applications@
sf.frb.org.
1. BlackRock, Inc., New York, New
York, on behalf of itself, its subsidiaries
and affiliates, and the accounts,
portfolios, registered and unregistered
investment companies, collective
investment vehicles, and other pooled
investment vehicles that are sponsored,
managed, or advised by BlackRock; to
acquire additional voting shares of
Banner Corporation, and thereby
indirectly acquire additional voting
shares of Banner Bank, both of Walla
Walla, Washington.
Board of Governors of the Federal Reserve
System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2023–12745 Filed 6–13–23; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Supplemental Evidence and Data
Request on Evaluation of Dietary
Protein Intake Requirements
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Request for supplemental
evidence and data submissions.
AGENCY:
The Agency for Healthcare
Research and Quality (AHRQ) is seeking
scientific information submissions from
the public. Scientific information is
being solicited to inform our review on
Evaluation of Dietary Protein Intake
Requirements, which is currently being
conducted by the AHRQ’s Evidencebased Practice Centers (EPC) Program.
Access to published and unpublished
pertinent scientific information will
improve the quality of this review.
DATES: Submission Deadline on or
before July 14, 2023.
ADDRESSES:
Email submissions: epc@
ahrq.hhs.gov.
Print submissions:
Mailing Address: Center for Evidence
and Practice Improvement, Agency for
Healthcare Research and Quality,
SUMMARY:
E:\FR\FM\14JNN1.SGM
14JNN1
Federal Register / Vol. 88, No. 114 / Wednesday, June 14, 2023 / Notices
ATTN: EPC SEADs Coordinator, 5600
Fishers Lane, Mail Stop 06E53A,
Rockville, MD 20857.
Shipping Address (FedEx, UPS, etc.):
Center for Evidence and Practice
Improvement, Agency for Healthcare
Research and Quality, ATTN: EPC
SEADs Coordinator, 5600 Fishers Lane,
Mail Stop 06E53A, Rockville, MD
20857.
FOR FURTHER INFORMATION CONTACT:
Kelly Carper, Telephone: 301–427–1656
or Email: epc@ahrq.hhs.gov.
The
Agency for Healthcare Research and
Quality has commissioned the
Evidence-based Practice Centers (EPC)
Program to complete a review of the
evidence for Evaluation of Dietary
Protein Intake Requirements. AHRQ is
conducting this systematic review
pursuant to section 902 of the Public
Health Service Act, 42 U.S.C. 299a.
The EPC Program is dedicated to
identifying as many studies as possible
that are relevant to the questions for
each of its reviews. In order to do so, we
are supplementing the usual manual
and electronic database searches of the
literature by requesting information
from the public (e.g., details of studies
conducted). We are looking for studies
that report on Evaluation of Dietary
Protein Intake Requirements, including
those that describe adverse events. The
entire research protocol is available
online at: https://
SUPPLEMENTARY INFORMATION:
effectivehealthcare.ahrq.gov/products/
dietary-protein-intake/protocol.
This is to notify the public that the
EPC Program would find the following
information on Evaluation of Dietary
Protein Intake Requirements helpful:
D A list of completed studies that
your organization has sponsored for this
indication. In the list, please indicate
whether results are available on
ClinicalTrials.gov along with the
ClinicalTrials.gov trial number.
D For completed studies that do not
have results on ClinicalTrials.gov, a
summary, including the following
elements: study number, study period,
design, methodology, indication and
diagnosis, proper use instructions,
inclusion and exclusion criteria,
primary and secondary outcomes,
baseline characteristics, number of
patients screened/eligible/enrolled/lost
to follow-up/withdrawn/analyzed,
effectiveness/efficacy, and safety results.
D A list of ongoing studies that your
organization has sponsored for this
indication. In the list, please provide the
ClinicalTrials.gov trial number or, if the
trial is not registered, the protocol for
the study including a study number, the
study period, design, methodology,
indication and diagnosis, proper use
instructions, inclusion and exclusion
criteria, and primary and secondary
outcomes.
D Description of whether the above
studies constitute ALL Phase II and
above clinical trials sponsored by your
organization for this indication and an
38865
index outlining the relevant information
in each submitted file.
Your contribution is very beneficial to
the Program. Materials submitted must
be publicly available or able to be made
public. Materials that are considered
confidential; marketing materials; study
types not included in the review; or
information on indications not included
in the review cannot be used by the EPC
Program. This is a voluntary request for
information, and all costs for complying
with this request must be borne by the
submitter.
The draft of this review will be posted
on AHRQ’s EPC Program website and
available for public comment for a
period of 4 weeks. If you would like to
be notified when the draft is posted,
please sign up for the email list at:
https://
www.effectivehealthcare.ahrq.gov/
email-updates.
The systematic review will answer the
following questions. This information is
provided as background. AHRQ is not
requesting that the public provide
answers to these questions.
Key Questions (KQ)
KQ 1: What is the average daily
dietary protein intake requirements of
apparently healthy individuals by life
stage and sex?
KQ 2: What is the average daily
dietary individual indispensable amino
acid intake requirements of apparently
healthy individuals by life stage and
sex?
ddrumheller on DSK120RN23PROD with NOTICES1
POPULATION, INTERVENTION, COMPARATOR, OUTCOME, TIMING, SETTING/STUDY DESIGN (PICOTS)
Element
Inclusion criteria
Exclusion criteria
Population KQ1 & 2 .............
• Participants who are healthy and/or have chronic diseases or chronic disease risk factors, including those
with obesity
• Studies that enroll some participants diagnosed with
a disease or hospitalized or in a long-term care facility with an illness or injury
• Studies that enroll some participants diagnosed with
a disease or with the health outcome of interest
• Participants who are pregnant and lactating.
• Age at intervention exposure:
Æ Infants, children, adolescents (0–18 years).
Æ Adults (19–64).
Æ Older adults (65 years and older).
Interventions KQ1 & 2 .........
• Total daily protein intake level
• Total daily intake of indispensable AAs (Histidine,
Isoleucine, Leucine, Lysine, Methionine,
Phenylalanine, Threonine, Tryptophan, Valine)
• Studies that exclusively enroll participants diagnosed
with a disease, hospitalized, or in a long-term care
facility with an illness or injury (for this criterion, studies that exclusively enroll participants with obesity will
not be excluded).
• Studies that aim to treat participants who have already been diagnosed with the outcome of interest
(except weight loss interventions in overweight or
obese subjects).
• Studies that exclusively enroll undernourished participants.
• Studies that exclusively enroll participants with a
baseline diet deficient in protein.
• Studies that exclusively enroll preterm infants.
• Studies that exclusively enroll post-bariatric surgery
subjects.
• Studies that exclusively recruit elite athletes.
• Participants with existing conditions that clearly are
known to alter nutrient metabolism or requirements,
or those being treated with medications that alter nutrient metabolism.
• Studies that only assess protein intake via infusions
(rather than the GI tract).
• Studies that examine food products or dietary supplements not widely available to U.S. consumers.
VerDate Sep<11>2014
19:24 Jun 13, 2023
Jkt 259001
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
E:\FR\FM\14JNN1.SGM
14JNN1
38866
Federal Register / Vol. 88, No. 114 / Wednesday, June 14, 2023 / Notices
POPULATION, INTERVENTION, COMPARATOR, OUTCOME, TIMING, SETTING/STUDY DESIGN (PICOTS)—Continued
Element
Comparison KQ1 & 2 ...........
Outcomes KQ1 ....................
Outcomes KQ2 ....................
Timing KQ1 & 2 ...................
Setting KQ1 & 2 ...................
Study Design KQ1 & 2 ........
Inclusion criteria
Exclusion criteria
• Different total daily protein intake level
• Different total daily intake of indispensable AAs
Total protein requirement * as defined by the following
indicators or criterion of adequacy, including but not
limited to:
• Nitrogen balance method
• Factorial method
• Indicator AA oxidation method
• Mean protein intake of infants fed principally human
milk (0–6 months)
• Mean protein content of human milk (0–6 months)
• Body composition (lean mass)
• Linear growth for infants, children, adolescents (0–18
years)
• Activities of daily living for older adults (65 years and
older)
Indispensable AA requirement* as defined by the following indicators of adequacy, including but not limited to:
• Plasma AA response method
• Direct AA oxidation method
• 24-hour AA balance method
• Indicator AA oxidation method
• Mean AA intake of infants fed principally human milk
(0–6 months)
• Mean protein content of human milk (0–6 months)
• All duration and follow up
• All settings
• Randomized controlled trials
• Non-randomized controlled trials, including quasi-experimental and controlled before-and-after studies
• Prospective cohort studies
• Nested case-control studies
Study Size KQ1 & 2 .............
Language KQ1 & 2 ..............
Geographic Location KQ1 &
2.
Publication Date KQ1 & 2 ....
Publication Status KQ1 & 2
• English only (due to resource limitations)
• Locations with food products or dietary supplements
widely available to U.S. consumers, including those
rated very high on the Human Development Index
• 2000 to present
• Articles published in peer-reviewed journals
• Multi-component interventions that do not isolate the
effect or association of protein (including protein and
exercise combinations).
• No comparator.
• International and government reports.
• Narrative reviews.
• Systematic reviews, meta-analyses, umbrella reviews, scoping reviews.
• Uncontrolled trials.
• Case-control studies.
• Uncontrolled before-and-after studies.
• Retrospective cohort studies.
• N < 6 participants and without power for crossover
studies.
• Other studies with N < 50 participants (for RCTs—25
participants analyzed per study arm), and without
power calculations.
• Articles that have not been peer reviewed and are
not published in peer-reviewed journals (e.g., unpublished data, manuscripts, pre-prints, reports, abstracts, conference proceedings).
ddrumheller on DSK120RN23PROD with NOTICES1
* Requirement is defined as the lowest daily intake value for a nutrient that will meet the need as defined by a specified indicator or criterion of
adequacy, of apparently healthy individuals.
Dated: June 8, 2023.
Marquita Cullom,
Associate Director.
[FR Doc. 2023–12677 Filed 6–13–23; 8:45 am]
BILLING CODE 4160–90–P
VerDate Sep<11>2014
19:24 Jun 13, 2023
Jkt 259001
PO 00000
Frm 00058
Fmt 4703
Sfmt 9990
E:\FR\FM\14JNN1.SGM
14JNN1
]]>Agencies
[Federal Register Volume 88, Number 114 (Wednesday, June 14, 2023)]
[Notices]
[Pages 38864-38866]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-12677]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Supplemental Evidence and Data Request on Evaluation of Dietary
Protein Intake Requirements
AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.
ACTION: Request for supplemental evidence and data submissions.
-----------------------------------------------------------------------
SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) is
seeking scientific information submissions from the public. Scientific
information is being solicited to inform our review on Evaluation of
Dietary Protein Intake Requirements, which is currently being conducted
by the AHRQ's Evidence-based Practice Centers (EPC) Program. Access to
published and unpublished pertinent scientific information will improve
the quality of this review.
DATES: Submission Deadline on or before July 14, 2023.
ADDRESSES:
Email submissions: [email protected].
Print submissions:
Mailing Address: Center for Evidence and Practice Improvement,
Agency for Healthcare Research and Quality,
[[Page 38865]]
ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E53A,
Rockville, MD 20857.
Shipping Address (FedEx, UPS, etc.): Center for Evidence and
Practice Improvement, Agency for Healthcare Research and Quality, ATTN:
EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E53A, Rockville,
MD 20857.
FOR FURTHER INFORMATION CONTACT: Kelly Carper, Telephone: 301-427-1656
or Email: [email protected].
SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and
Quality has commissioned the Evidence-based Practice Centers (EPC)
Program to complete a review of the evidence for Evaluation of Dietary
Protein Intake Requirements. AHRQ is conducting this systematic review
pursuant to section 902 of the Public Health Service Act, 42 U.S.C.
299a.
The EPC Program is dedicated to identifying as many studies as
possible that are relevant to the questions for each of its reviews. In
order to do so, we are supplementing the usual manual and electronic
database searches of the literature by requesting information from the
public (e.g., details of studies conducted). We are looking for studies
that report on Evaluation of Dietary Protein Intake Requirements,
including those that describe adverse events. The entire research
protocol is available online at: https://effectivehealthcare.ahrq.gov/products/dietary-protein-intake/protocol.
This is to notify the public that the EPC Program would find the
following information on Evaluation of Dietary Protein Intake
Requirements helpful:
[ssquf] A list of completed studies that your organization has
sponsored for this indication. In the list, please indicate whether
results are available on ClinicalTrials.gov along with the
ClinicalTrials.gov trial number.
[ssquf] For completed studies that do not have results on
ClinicalTrials.gov, a summary, including the following elements: study
number, study period, design, methodology, indication and diagnosis,
proper use instructions, inclusion and exclusion criteria, primary and
secondary outcomes, baseline characteristics, number of patients
screened/eligible/enrolled/lost to follow-up/withdrawn/analyzed,
effectiveness/efficacy, and safety results.
[ssquf] A list of ongoing studies that your organization has
sponsored for this indication. In the list, please provide the
ClinicalTrials.gov trial number or, if the trial is not registered, the
protocol for the study including a study number, the study period,
design, methodology, indication and diagnosis, proper use instructions,
inclusion and exclusion criteria, and primary and secondary outcomes.
[ssquf] Description of whether the above studies constitute ALL
Phase II and above clinical trials sponsored by your organization for
this indication and an index outlining the relevant information in each
submitted file.
Your contribution is very beneficial to the Program. Materials
submitted must be publicly available or able to be made public.
Materials that are considered confidential; marketing materials; study
types not included in the review; or information on indications not
included in the review cannot be used by the EPC Program. This is a
voluntary request for information, and all costs for complying with
this request must be borne by the submitter.
The draft of this review will be posted on AHRQ's EPC Program
website and available for public comment for a period of 4 weeks. If
you would like to be notified when the draft is posted, please sign up
for the email list at: https://www.effectivehealthcare.ahrq.gov/email-updates.
The systematic review will answer the following questions. This
information is provided as background. AHRQ is not requesting that the
public provide answers to these questions.
Key Questions (KQ)
KQ 1: What is the average daily dietary protein intake requirements
of apparently healthy individuals by life stage and sex?
KQ 2: What is the average daily dietary individual indispensable
amino acid intake requirements of apparently healthy individuals by
life stage and sex?
Population, Intervention, Comparator, Outcome, Timing, Setting/Study Design (PICOTS)
----------------------------------------------------------------------------------------------------------------
Element Inclusion criteria Exclusion criteria
----------------------------------------------------------------------------------------------------------------
Population KQ1 & 2............... Participants who are healthy Studies that exclusively
and/or have chronic diseases or enroll participants diagnosed with a
chronic disease risk factors, disease, hospitalized, or in a long-
including those with obesity term care facility with an illness
Studies that enroll some or injury (for this criterion,
participants diagnosed with a disease studies that exclusively enroll
or hospitalized or in a long-term participants with obesity will not
care facility with an illness or be excluded).
injury Studies that aim to treat
Studies that enroll some participants who have already been
participants diagnosed with a disease diagnosed with the outcome of
or with the health outcome of interest (except weight loss
interest interventions in overweight or obese
Participants who are pregnant subjects).
and lactating. Studies that exclusively
Age at intervention exposure: enroll undernourished participants.
[cir] Infants, children, adolescents Studies that exclusively
(0-18 years). enroll participants with a baseline
[cir] Adults (19-64). diet deficient in protein.
[cir] Older adults (65 years and Studies that exclusively
older). enroll preterm infants.
Studies that exclusively
enroll post-bariatric surgery
subjects.
Studies that exclusively
recruit elite athletes.
Participants with existing
conditions that clearly are known to
alter nutrient metabolism or
requirements, or those being treated
with medications that alter nutrient
metabolism.
Interventions KQ1 & 2............ Total daily protein intake Studies that only assess
level protein intake via infusions (rather
Total daily intake of than the GI tract).
indispensable AAs (Histidine, Studies that examine food
Isoleucine, Leucine, Lysine, products or dietary supplements not
Methionine, Phenylalanine, Threonine, widely available to U.S. consumers.
Tryptophan, Valine)
[[Page 38866]]
Multi-component
interventions that do not isolate
the effect or association of protein
(including protein and exercise
combinations).
Comparison KQ1 & 2............... Different total daily protein No comparator.
intake level
Different total daily intake
of indispensable AAs
Outcomes KQ1..................... Total protein requirement * as defined
by the following indicators or
criterion of adequacy, including but
not limited to:
Nitrogen balance method
Factorial method
Indicator AA oxidation method
Mean protein intake of
infants fed principally human milk (0-
6 months)
Mean protein content of human
milk (0-6 months)
Body composition (lean mass)
Linear growth for infants,
children, adolescents (0-18 years)
Activities of daily living
for older adults (65 years and older)
Outcomes KQ2..................... Indispensable AA requirement* as
defined by the following indicators
of adequacy, including but not
limited to:
Plasma AA response method
Direct AA oxidation method
24-hour AA balance method
Indicator AA oxidation method
Mean AA intake of infants fed
principally human milk (0-6 months)
Mean protein content of human
milk (0-6 months)
Timing KQ1 & 2................... All duration and follow up
Setting KQ1 & 2.................. All settings
Study Design KQ1 & 2............. Randomized controlled trials International and government
Non-randomized controlled reports.
trials, including quasi-experimental
and controlled before-and-after
studies
Narrative reviews.
Prospective cohort studies Systematic reviews, meta-
Nested case-control studies analyses, umbrella reviews, scoping
reviews.
Uncontrolled trials.
Case-control studies.
Uncontrolled before-and-
after studies.
Retrospective cohort
studies.
Study Size KQ1 & 2............... N < 6 participants and
without power for crossover studies.
Other studies with N < 50
participants (for RCTs--25
participants analyzed per study
arm), and without power
calculations.
Language KQ1 & 2................. English only (due to resource
limitations)
Geographic Location KQ1 & 2...... Locations with food products
or dietary supplements widely
available to U.S. consumers,
including those rated very high on
the Human Development Index
Publication Date KQ1 & 2......... 2000 to present
Publication Status KQ1 & 2....... Articles published in peer- Articles that have not been
reviewed journals peer reviewed and are not published
in peer-reviewed journals (e.g.,
unpublished data, manuscripts, pre-
prints, reports, abstracts,
conference proceedings).
----------------------------------------------------------------------------------------------------------------
* Requirement is defined as the lowest daily intake value for a nutrient that will meet the need as defined by a
specified indicator or criterion of adequacy, of apparently healthy individuals.
Dated: June 8, 2023.
Marquita Cullom,
Associate Director.
[FR Doc. 2023-12677 Filed 6-13-23; 8:45 am]
BILLING CODE 4160-90-P
